Zalecenia Polskiego Towarzystwa Chorób Płuc rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc (POChP)

Pneumonologia i Alergologia Polska

Volumn 78, Issue 5, 2010, Pages 318-347

  Pierzchała, Władysław ^a   Barczyk, Adam ^a   Górecka, Dorota ^a   Śliwiński, Paweł ^a   Zieliński, Jan ^a   Jankowska, Renata ^a   Małolepszy, Józef ^a   Słomiński, Jan Marek ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL COMPETENCE; CLINICAL PRACTICE; DIFFERENTIAL DIAGNOSIS; HUMAN; MEDICAL SOCIETY; ORGANIZATION AND MANAGEMENT; POLAND; PRACTICE GUIDELINE; PULMONOLOGY; RISK FACTOR; STANDARD; STATISTICS; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; CLINICAL COMPETENCE; DIAGNOSIS, DIFFERENTIAL; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; POLAND; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 77958193385     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (171)

1. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004; 23: 932-946.
2. Rabe K.F., Hurd S., Anzueto A. i wsp.; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-555.
3. Halbert R.J., Natoli J.L., Gano A. i wsp. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 2006; 28: 523-532.
4. Jemal A., Ward E., Hao Y., Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-1259.
5. Murray C.J.L., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-1504.
6. Niepsuj G., Kozielski J., Niepsuj K. i wsp. Przewlekła obturacyjna choroba płuc wŚród mieszkańców Zabrza. Wiad. Lek. 2002; 55 (supl. 1): 354-359.
7. Nizankowska-Mogilnicka E., Mejza F., Buist A.S. i wsp. Prevalence of COPD and tobacco smoking in Malopolska region-results from the BOLD study in Poland. Pol. Arch. Med. Wewn. 2007; 117: 402-410.
8. Bednarek M., Maciejewski J., Wozniak M. i wsp. Prevalence, severity and underdiagnosis of COPD in the primary care setting. Thorax 2008; 63: 402-407.
9. Rocznik statystyczny Rzeczpospolitej Polskiej. Główny Urza̧d Statystyczny 2008; 204.
10. Korzeniewska-Koseła M. (red). Gruźlica i choroby układu oddechowego w Polsce. Instytut Gruźlicy i Chorób Płuc, Warszawa 2008.
11. Young R.P., Hopkins R., Eaton T.E. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur. Respir. J. 2007; 30: 616-622.
12. Blanc P.D., Menezes A.M., Plana E. i wsp. Occupational exposures and COPD: an ecological analysis of international data. Eur. Respir. J. 2009; 33: 298-304.
13. Hnizdo E., Sullivan P.A., Bang K.M. i wsp. Association between chronic obstructive pulmonary disease and employment by industry and occupation in the US population: a study of data from the Third National Health and Nutrition examination survey. Am. J. Epidemiol. 2002; 156: 738-746.
14. Schindler C., Keidel D., Gerbase M.W. i wsp. Improvements in PM 1O exposure and reduced rates of respiratory symptoms in a cohort of Swiss adults (SAPALDIA). Am. J. Respir. Crit. Care Med. 2009; 179: 579-587.
15. Barker D.J.P., Godfrey K.M., Fall C.H.D. i wsp. Relation of birthweight and childhood respiratory infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991; 303 :671-675.
16. Stoller J.K., Aboussouan L.S. a1-antitrypsin deficiency. Lancet 2005; 365: 2225-2236.
17. Barnes P.J., Shapiro S.D., Pauwels R.A. Chronic obstructive pulmonary disease: molecular and cellular mechanism. Eur. Respir. J. 2003; 22: 672-688.
18. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur. J. Pharmacol. 2001; 429: 195-207.
19. Barnes P.J. Macrophages as orchestrators of COPD. J. COPD 2004; 1: 59-70.
20. 1. Am. J. Respir. Crit. Care Med. 1997; 155: 852-857.
21. Thompson A.B., Daughton D., Robbins R.A. i wsp. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am. Rev. Respir. Dis. 1989; 140: 1527-1537.
22. Hogg J.C., Chu F., Utokaparch S. i wsp. The nature of smallairway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 2645-2653.
23. Hardie J.A., Buist A.S., Vollmer W.M. i wsp. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur. Respir. J. 2002; 20: 1117-1122.
24. Vollmer W.M., Gislason P., Burney P. i wsp. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur. Respir. J. 2009; 34: 588-597.
25. Quanjer Ph.H., Tammeling G.J., Cotes J.E. i wsp. Lung volumes and forced ventilatory flows. Official statement of the European Respiratory Society. Eur. Respir. J. 1993; 16 (supl.): 5-40.
26. Falaschetti E., Laiho J., Primatesta P., Purdon S. Prediction equations for normal and low lung function from the Health Survey for England. Eur. Respir. J. 2004; 23: 456-463.
27. Sobradillo-Peńa V., Miravitlles M., Gabriel R. i wsp. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest 2000; 118: 981-989.
28. Fukuchi Y., Nishimura M., Ichinose M. i wsp. COPD in Japan the Nippon COPD epidemiological study. Respirology 2004; 9: 458-465.
29. 1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am. J. Respir. Crit. Care Med. 1996; 153: 1530-1535.
30. Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J. 1977; 1: 1645-1648.
31. Burrows B., Kettel L.J., Niden A.H. i wsp. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N. Engl. J. Med. 1972; 286: 912-918.
32. Celli B.R., Cote C.G., Marin J.M. i wsp. The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350: 1005-1012.
33. Rennard S.I., Vestbo J. Natural histories of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2008; 5: 878-883.
34. Anthonisen N.R., Connett J.E., Murray R.P. for the Lung Health Study Research Group. Smoking and lung function of Lung Health Study participants after 11 years. Am. J. Respir. Crit. Care Med. 2002; 166: 675-679.
35. Zieliński J., Bednarek M., Górecka D. w imieniu grupy "Poznaj wiek swoich płuc". Narodowy Program Wczesnego Rozpoznawania i Profilaktyki POChP w latach 2000-2002. Pneumonol. Alergol. Pol. 2005; 73: 116-121.
36. Buffels J., Degryse J., Heyrman J., Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004; 125: 1394-1399.
37. Kohansal R., Martinez-Camblor P., Agusti A. i wsp. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am. J. Respir. Crit. Care Med. 2009; 180: 3-10.
38. Lin K., Watkins B., Johnson T. i wsp. Screening for chronic obstructive pulmonary disease using spirometry: summary of the evidence for the US Preventive Services Task Force. Ann. Intern. Med. 2008; 148: 535-543.
39. Anthonisen N.R., Skeans M.A., Wise R.A. i wsp. Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233-239.
40. Kohansal R., Soriano J.B., Agusti A. Investigating the natural history of lung function: facts, pitfalls, and opportunities. Chest 2009; 135: 1330-1341.
41. West R., McNeill A., Raw M. Smoking cessation guidelines for health professionals: an update. Health Education Authority. Thorax 2000; 55: 987-999.
42. Górecka D., Bednarek M., Nowiński A. i wsp. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. Chest 2003; 123: 1916-1923.
43. Bednarek M., Gorecka D., Wielgomas J. i wsp. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006; 61: 869-873.
44. Silagy C., Lancaster T., Stead L. i wsp. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst. Rev. 2004; (3): CD000146.
45. Review. Update in: Cochrane Database Syst. Rev. 2008; (1): CD000146.
46. Jorenby D.E., Leischow S.J., Nides M.A. i wsp. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N. Engl. J. Med. 1999; 340: 685-691.
47. Tashkin D., Kanner R., Bailey W. i wsp. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 2001; 357: 1571-1575.
48. Cahill K., Stead L.F., Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst. Rev. 2008; Issue 3: CD006103.
49. 2008 PHS Guideline Update Panel, Liaisons, and Staff. Treating tobacco use and dependence: 2008 update U.S. Public Health Service Clinical Practice Guideline executive summary. Respir. Care 2008; 53: 1217-1222.
50. Torres-Duque C., Maldonaldo D., Perez-Padilla R. i wsp. w imieniu Forum of International Respiratory Studies (FIRS) Task Force on Health Effects of Biomass Exposure. Biomass fuels and respiratory diseases: a review of evidence. Proc. Am. Thorac. Soc. 2008; 5: 577-590.
51. Poole P.J., Chacko E., Wood-Baker R.W., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006 25; (1): CD002733.
52. Schembri S., Morant S., Winter J.H., MacDonald T.M. Influenza but not pneumococcal vaccination protects against all-cause mortality in patients with COPD. Thorax 2009; 64: 567-572.
53. Schenkein J.G., Nahm M.H., Dransfield M.T. Pneumococcal vaccination for patients with COPD: current practice and future directions. Chest 2008; 133: 767-774.
54. Dransfield M.T., Nahm M.H., Han M.K. i wsp. COPD Clinical Research Network. Superior immune response to protein-conjugate versus free pneumococcal polysaccharide vaccine in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 499-505.
55. Furumoto A., Ohkusa Y., Chen M. i wsp. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26: 4284-4289.
56. Zalecenia Polskiego Towarzystwa Ftizjopneumonologicznego rozpoznawania i leczenia przewlekłej obturacyjnej choroby płuc (POChP). Pneumonol. Alergol. Pol. 2004; 72 (supl. 1).
57. Rodrigo G.J., Nannini L.J., Rodriguez-Roisin R. Safety of longacting beta-agonists in stable COPD: a systematic review. Chest 2008; 133: 1079-1087.
58. Tashkin D.P., Celli B., Senn S. i wsp. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 1543-1554.
59. Decramer M., Celli B., Kesten S. i wsp. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet 2009; 374: 1171-1178.
60. Wedzicha J.A., Calverley P.M., Seemungal T.A. i wsp. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am. J. Respir. Crit. Care Med. 2008; 177: 19-26.
61. Johansson G., Lindberg A., Romberg K., Nordstrom L., Gerken F., Roquet A. Bronchodilator efficacy of tiotropium in patients with mild to moderate COPD. Prim. Care Respir. J. 2008; 17: 169-175.
62. Barr R.G., Rowe B.H., Camargo C.A. Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials. BMJ 2003; 327: 6436-649.
63. Di Marco F., Verga M., Santus P. i wsp. Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study. Respir. Med. 2006; 100: 1925-1932.
64. Walters J.A., Gibson P.G., Wood-Baker R., Hannay M., Walters E.H. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2009; (1): CD001288.
65. Burge P.S., Calverley P.M., Jones P.W., Spencer S., Anderson J.A. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003; 58: 654-658.
66. Alsaeedi A., Sin D.D., McAlister F.A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. 2002; 113: 59-65.
67. Calverley P., Pauwels R., Vestbo J. i wsp. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361: 449-456.
68. Szafranski W., Cukier A., Ramirez A. i wsp. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.
69. Calverley P.M., Anderson J.A., Celli B. i wsp. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775-789.
70. Nannini L., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (4): CD003794.
71. Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (4): CD006826.
72. Nannini L.J., Cates C.J., Lasserson T.J., Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2007; (4): CD006829.
73. Celli B.R., Thomas N.E., Anderson J.A. i wsp. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med. 2008; 178: 332-338.
74. Jenkins C.R., Jones P.W., Calverley P.M.A. i wsp. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir. Res. 2009; 10: 59.
75. Singh D., Brooks J., Hagan G., Cahn A., O'Connor B.J. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-598.
76. Aaron S.D., Vandemheen K.L., Fergusson D. i wsp. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555.
77. Calverley P.M., Sanchez-Toril F., McIvor A. i wsp. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2007; 176: 154-161.
78. Rennard S.I., Schachter N., Strek M., Rickard K., Amit O. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest 2006; 129: 56-66.
79. Calverley P.M., Rabe K.F., Goehring U.M. i wsp. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694.
80. Fabbri L.M., Calverley P.M., Izquierdo-Alonso J.L. i wsp. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long acting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703.
81. Poole P., Black P.N. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database of Systemic Reviews. 2006; Issue 3: Art. No: CD001287.
82. Zieliński J., Tobiasz M., Hawryłkiewicz I., Śliwiński P., Pałasiewicz G. Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients. Chest 1998; 113: 65-70.
83. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy m hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391-398.
84. Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1 (8222): 681-686.
85. Pływaczewski R., Śliwiński P., Nowiński A. i wsp. Incidence of nocturnal desaturation while breathing oxygen in COPD patients undergoing long-term oxygen therapy. Chest 2000; 117: 679-683.
86. Skwarski K. Nocna hipoksemia i zaburzenia rytmu serca u chorych z przewlekła̧ obturacyjna̧ choroba̧ płuc. Pol. Arch. Med. Wewn. 1989; 81: 283-294.
87. Śliwiński P., Łagosz M., Górecka D., Zieliński J. The adequacy of oxygenation in COPD patients undergoing long-term oxygen therapy assessed by pulse oximetry at home. Eur. Respir. J. 1994; 7: 274-278.
88. Goldstein R.S., Ramcharan C., Bowes G. i wsp. Effect of supplemental oxygen on gas exchange in patients with severe obstructive lung disease. N. Engl. J. Med. 1984; 310: 425-429.
89. O'Donnell D.E., Sain D.J., Webb K.A. Factors contributing to relief of exertional breathlessness during hyperoxia in chronic airflow limitation. Am. J. Respir. Crit. Care Med. 1997; 155: 530-535.
90. Somfay A., Porszasz J., Lee S.M., Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in nonhypoxaemic COPD patents. Eur. Respir. J. 2001; 18: 77-84.
91. Gong H. Jr. An air travel and oxygen therapy in cardiopulmonary patients. Chest 1992; 101: 1104-1113.
92. Gong H. Jr., Taskhin D.P., Lee E.Y., Simmons M.S. Hypoxia altitude simulation test. Evaluation of patients with chronic airway obstruction. Am. Rev. Respir. Dis. 1984; 130: 980-986.
93. Berg B.W., Dislard T.A., Rajagopal K.R., Mehm W.J. Oxygen supplementation during air travel in patients with chronic obstructive lung disease. Chest 1992; 10: 638-641.
94. Walker J., Kelly P.T., Beckert L. Air line policy for passengers requiring supplemental in-fligh oxygen. Respirology 2009; 14: 589-594.
95. Mehran R.J., Deslauriers J. Indication for surgery and patient workup for bullectomy Chest Surg. Clin. N. Am. 1995; 5: 717-734.
96. Hughes J.A., MacArthur A.M., Hutchison D.C., Hugh-Jones P. Lung term changes in lung function after surgical treatment of bullous emphysema in smokers and ex-smokers. Thorax 1984; 39: 140-142.
97. Laros C.D., Gelissen H.J., Bergstein P.G. i wsp. Bullactomy for giant bullae in emphysema. J. Thorac. Cardiovasc. Surg. 1986; 91: 63-70.
98. Flaherty K.R., Kazerooni E.A., Curtis J.L. i wsp. Short-term and long-term outcomes after bilateral lung volume reduction surgery: prediction by quantitative CT. Chest 2001; 119: 1337-1346.
99. Gelb A.F., McKenna R.J. Jr, Brenner M. i wsp. Lung function 5 yr after lung volume reduction surgery for emphysema. Am. J. Respir. Crit. Care Med. 2001; 163: 1562-1566.
100. Naunheim K.S., Wood D.E., Mohsenifar Z. i wsp. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann. Thorac. Surg. 2006; 82: 431-443.
101. Hamacher J., Russi E.W., Weder W. Lung volume reduction surgery: a survey on the European experience. Chest 2000; 117: 1560-1567.
102. Hosenpud J.D., Bennett L.E., Keck B.M. i wsp. The Registry of the International Society for Heart and Lung Transplantation: fifteenth official report-1998. J. Heart Lung Transplant. 1998; 17: 656-668.
103. Maurer J.R., Frost A.E., Estenne M., Higenbottam T., Glanville A.R. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. Transplantation 1998; 66: 951-956.
104. Gosselink R., Troosters T., Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am. J. Respir. Crit. Care Med. 1996; 153: 976-980. (Pubitemid 26081648)
105. Goldstein R.S., Gort E.H., Stubbing D. i wsp. Randomised controlled trial of respiratory rehabilitation. Lancet 1994; 344: 1394-1397.
106. Troosters T., Casaburi R., Gosselink R., Decramer M. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 19-38. (Pubitemid 40923311)
107. O'Donnell D.E., McGuire M., Samis L. i wsp. The impact of exercise reconditioning on breathlessness in severe chronic airflow limitation. Am. J. Respir. Crit. Care Med. 1995; 152: 2005-2013.
108. Casaburi R., Kukafka D., Cooper C.B., Witek T.J. Jr., Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-817.
109. Behnke M., Taube C., Kirsten D. i wsp. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir. Med. 2000; 94: 1184-1191.
110. Troosters T., Gosselink R., Decramer M. Short and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease a randomized trial. Am. J. Med. 2000; 109: 207-212.
111. Finnerty J.P., Keeping I., Bulfough I., Jones J. The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: a randomized controlled trial. Chest 2001; 119: 1705-1710.
112. Green R.H., Singh S.J., Williams J., Morgan M.D. A randomized controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2001; 58: 143-145.
113. Gibson P.G., Wlodarczyk J.H., Wilson A.J., Sprogis A. Severe exacerbation of chronic obstructive airways disease: health resource use in general practice and hospital. J. Qual. Clin. Pract. 1998; 18: 125-133.
114. Mahler D.A. Pulmonary rehabilitation. Chest 1998; 113: 263S-268S.
115. Bernard S., Whittom F., Leblanc P. i wsp. Aerobic and strength training it patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1990; 159: 896-901.
116. Smith K., Cook D., Guyatt G.H. i wsp. Respiratory muscle training in chronic airflow limitation: a meta-analysis. Am. Rev. Respir. Dis. 1992; 145: 533-539.
117. Lotters F., van Tol B., Kwakkel G., Gosselink R. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur. Respir. J. 2002; 20: 570-576.
118. Brochard L., Mancebo J., Wysocki M. i wsp. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 1995; 333: 817-822.
119. Hillberg R.E., Johnson D.C. Noninvasive ventilation. N. Engl. J. Med. 1997; 337: 1746-1752.
120. Muir J.F., Cuvelier A., Verin E. i wsp. Noninvasive mechanical ventilation and acute respiratory failure: indications and limitations. Monaldi Arch. Chest Dis. 1997; 52: 56-59.
121. Elliott M.W. Noninvasive ventilation in chronic ventilatory failure due to chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 20: 511-514.
122. Consensus conference report. Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation. Chest 1999; 116: 521-534.
123. Clini E., Sturani C., Rossi A. i wsp. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur. Respir. J. 2002; 20: 529-538.
124. Pingleton S.K. Invasive mechanical ventilation in exacerbations of chronic obstructive pulmonary disease. Monaldi Arch. Chest Dis. 1998; 53: 337-342.
125. Purro A., Appendini L., De Gaetano A. i wsp. Physiologic determinants of ventilator dependence in long-term mechanically ventilated patients. Am. J. Respir. Crit. Care Med. 2000; 161: 1115-1123.
126. Nava S., Rubini F., Zanotti E. i wsp. Survival and prediction of successful ventilator weaning in COPD patients requiring mechanical ventilation for more than 21 days. Eur. Respir. J. 1994; 7: 1645-1652.
127. Nevins M.L., Epstein S.K. Predictors of outcome for patients with COPD requiring invasive mechanical ventilation. Chest 2001; 119: 1840-1849.
128. Esteban A., Anzueto A., Alia I. i wsp. How is mechanical ventilation employed in the intensive care unit? An international utilization review. Am. J. Respir. Crit. Care Med. 2000; 161:1450-1458.
129. Caramori G., Adcock I.M., Papi A. Clinical definition of COPD exacerbations and classification of their severity. South Med. J. 2009; 102: 277-282.
130. Pauwels R., Calverley P., Buist A.S. i wsp. COPD exacerbations: the importance of a standard definition. Respir. Med. 2004; 98: 99-107.
131. Anthonisen N.R., Manfreda J., Warren C.P. i wsp.. Antibiotic therapy -a exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.
132. Woodhead M., Blasi F., Ewig S. i wsp. ERS Task Force Report. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur. Respir. J. 1998; 11: 986-991.
133. Cazzola M., MacNee W., Martinez F.J. i wsp. American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur. Respir. J. 2008; 31: 416-469.
134. Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786-796.
135. Hurst J.R., Donaldson G.C., Wilkinson T.M. i wsp. Epidemiological relationships between the common cold and exacerbation frequency in COPD. Eur. Respir. J. 2005; 26: 846-852.
136. Seemungal T., Harper-Owen R., Bhowmik A. i wsp. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 164: 1618-1623.
137. Yang C.Y., Chen C.J. Air pollution and hospital admissions for chronic obstructive pulmonary disease in a subtropical city: Taipei, Taiwan. J. Toxicol. Environ. Health A. 2007; 70: 1214-1219.
138. Linaker C.H., Coggon D., Holgate S.T. i wsp. Personal exposure to nitrogen dioxide and risk of airflow obstruction in asthmatic children with upper respiratory infection. Thorax 2000; 55: 930-933.
139. Holguin F., Folch E., Redd S.C., Mannino D.M. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005-2011.
140. Tillie-Leblond I., Marquette C.H., Perez T. i wsp. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann. Intern. Med. 2006; 144: 390-396.
141. Smeeth L., Cook C., Thomas S. i wsp. Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting. Lancet 2006; 367: 1075-1079.
142. Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet 1999; 354: 456-460.
143. Niewoehner D.E., Erbland M.L., Deupree R.H. i wsp. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N. Engl. J. Med. 1999; 340: 1941-1947.
144. Roede B.M., Bresser P., Bindels P.J. i wsp. Antibiotic treatment is associated with reduced risk of a subsequent exacerbation in obstructive lung disease: an historical population based cohort study. Thorax 2008; 63: 968-973.
145. El Moussaoui R., Roede B.M., Speelman P. i wsp. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63: 415-422.
146. O'Donnell D.E., Aaron S., Bourbeau J. i wsp. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can. Respir. J. 2007; 14: 5B-32B.
147. Burge P.S., Calverley P.M., Jones P.W. i wsp. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
148. Lung Health Study Research Group: Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N. Engl. J. Med. 2000; 343: 1902-1909.
149. Niewoehner D.E., Rice K., Cote C. i wsp. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143: 317-326.
150. Casaburi R., Mahler D.A., Jones P.W. i wsp. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.
151. Rennard S.I., Anderson W., ZuWallack R. i wsp. Use of a long- acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1087-1092.
152. Aaron S.D., Vandemheen K.L., Fergusson D. i wsp. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555.
153. Gorse G.J., O'Connor T.Z., Young S.L. i wsp. Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. Chest 2006; 130: 1109-1116.
154. Alfageme I., Vazquez R., Reyes N. i wsp. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189-195.
155. Solèr M., Mütterlein R., Cozma G.; Swiss-German OM-85 Study Group. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration 2007; 74: 26-32.
156. Sprenkle M.D., Niewoehner D.E., MacDonald R., Rutks I., Wilt T.J. Clinical efficacy of OM-85 BV in COPD and chronic bronchitis: a systematic review. COPD 2005; 2: 167-175.
157. Kunik M., Rondy K., Veazey C. Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest 2005; 127: 1205-1211.
158. Bailey P. The dyspnea-anxiety-dyspnea cycle: COPD patients' stories of breathlessness. Qual. Health Res. 2004; 14: 760-778.
159. Gudmundsson G., Gislason T., Janson C. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur. Respir. J. 2005; 26: 414-419.
160. Voogd J., Wempe J., Koeter G. i wsp. Depressive symptoms as predictors of mortality in patients with COPD. Chest 2009; 135: 619-625.
161. Curtis J.R., Engelberg R.A., Nielsen E.L., Au D.H., Patrick D.L. Patient-physician communication about end-of-life for patients with severe COPD. Eur. Respir. J. 2004; 24: 200-205.
162. Jones I., Kirby A., Ormiston P. The needs of patients dying of chronic obstructive pulmonary disease in the community. Fam. Pract. 2004; 21: 310-313.
163. O'Donnell D.E., Banzett R.B., Carrieri-Kohlman V. i wsp. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc. Am. Thorac. Soc. 2007; 4: 145-168. (Pubitemid 46743309)
164. Paz-Diaz H., Montes de Oca M., Lopez J.M., Celli B.R. Pulmonary rehabilitation improves depression, anxiety, dyspnea and health status in patients with COPD. Am. J. Phys. Med. Rehabil. 2007; 86: 30-36.
165. Gore J.M., Brophy C.J., Greenstone M.A. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000; 55: 1000-1006.
166. Hung W.W., Visnivesky J.P., Siu A.L., Ross J.S. Cognitive decline among patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 134-137.
167. Virchow J.C., Crompton G.K., Dal Negro L. i wsp. Importance of inhaler devices in the management of airway disease. Respir. Med. 2008; 102: 10-19.
168. Budweiser S., Hitzl A.P., Jorres R.A. i wsp. Health-related quality of life and long-term prognosis in chronic hypercapnic respiratory failure: a prospective survival analysis. Respir. Res. 2007; 8: 1-9.
169. Groft M. Palliative care in end-stage COPD. Brit. J. Gen. Pract. 2005; 55: 234-235.
170. Murray S.A., Kendall M., Boyd K., Sheikh A. Illness trajectories and palliative care. BMJ 2005; 330: 1007-1011.
171. Buchanan R.J., Chakravorty B., Wang S. i wsp. Nursing home residents with emphysema/COPD compared to other residents. J. Soc. Work Disabil. Rehabil. 2004; 3: 53-78.